The following is a summary of the OraSure Technologies, Inc. (OSUR) Q1 2024 Earnings Call Transcript:

Financial Performance:

• OraSure reported Q1 revenue of $54.1 million, of which $31 million came from core revenue.

• The diagnostics segment contributed to $16.4 million in revenue, showing a decrease of 4% YoY, while the Molecular Sample Management Solutions sector decreased by 16% YoY to $10.8 million.

• The COVID-19 product, InteliSwab, contributed greatly with $23.1 million to Q1 revenue, exceeding forecasts.

• The company reported a gross margin of 44.5% and anticipates expansion and increased efficiency in the future.

Business Progress:

• OraSure is focusing on strengthening its foundation through organizational restructuring, improving its balance sheet, and generating cash flow.

• They have streamlined operations with cost reduction steps such as insourcing manufacturing activities and exiting certain businesses, expecting substantial cost savings over the next two years.

• They signed a multi-year deal with 23andMe and have initiated strategic partnerships with Sapphiros and Diagnostics Direct.

• The company also continues its successful free HIV testing program and anticipates growth in 2024 through product pipeline investment, partnerships, and potential acquisitions.

More details: OraSure Technologies IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.